Global Recombinant Protein Drugs research

Recombinant Protein Drugs Comprehensive Study by Application (Medicine, Research, Biotechnology, Others), Category (Protein, Monoclonal Antibody, Vaccine, Cytokines, Others) Players and Region - Global Market Outlook to 2026

Recombinant Protein Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
The study covers a detailed analysis segmented by key business segments i.e. , by application (Medicine, Research, Biotechnology and Others) and major geographies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Recombinant Protein Drugs market throughout the predicted period.

What is Recombinant Protein Drugs?
Recombinant protein drugs is also known as rDNA drugs. Recombinant proteins are artificially made with the recombinant DNA technology. The recombinant protein is effective and plays unique role in the treatment of certain diseases, such as hemophilia, except blood coagulation factor, which has an extremely limited source, it can only rely on the recombinant coagulation factor. Recombinant proteins are made up of amino acids that are attached to one another in chains. The recombinant DNA technology provides a more efficient method to obtain large amounts of proteins.

The competition is expected to become even more intense in the years to come due to entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Recombinant Protein Drugs market analysis report suggests strategies Players can follow and recommends key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, including:
  • Abcam PLC (United Kingdom)
  • Abnova Corporation (Taiwan)
  • Enzo Life Sciences Inc. (United States)
  • Eurogentec (Belgium)
  • ProSpec-Tany TechnoGene Ltd. (Israel)
  • Thermo Fisher Scientific Inc. (United States)
  • Merck Serono (Germany)
  • Kyowa Hakko Kirin (Japan)
  • BD Biosciences (United States)
  • Albumedix Ltd. (United Kingdom)


Market Overview:
On March 19, 2019- Merck, a leading science and technology company has announced the signing of a non-binding Memorandum of Understanding with Chinese biotech company GenScript for a strategic alliance focusing on plasmid and viral vector manufacturing.

Market Trend
Rising Prevalence of Chronic Diseases Such As Cancer and Increasing Investment on Research Activities
Restraints
  • Time-consuming Production Process

Opportunities
Introduction of New Protein Therapeutics

Key highlights of the Global Recombinant Protein Drugs market Study:
• CAGR of the market during the forecast period 2020-2026
• In-depth information on growth factors that will accelerate the Recombinant Protein Drugs market in next few years.
• Detailed Insights on futuristic trends and changing consumer behaviour
• Forecast of the Global Recombinant Protein Drugs market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Recombinant Protein Drugs Players

Transformation and Important Trigegrs:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Recombinant Protein Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Recombinant Protein Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes Manufacturers of Recombinant Protein Drugs, Suppliers of Recombinant Protein Drugs, Wholesalers, Distributors and Retailers of Recombinant Protein Drugs, Healthcare Industry, Research Organization, Biopharmaceutical Companies and Governmental Bodies.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Application
  • Medicine
  • Research
  • Biotechnology
  • Others
By Category
  • Protein
  • Monoclonal Antibody
  • Vaccine
  • Cytokines
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Demand for Biological Products
      • 3.2.2. Growing Inclination toward Biologics and Biosimilars
    • 3.3. Market Challenges
      • 3.3.1. High Price of Recombinant Protein Drugs
    • 3.4. Market Trends
      • 3.4.1. Rising Prevalence of Chronic Diseases Such As Cancer
      • 3.4.2. Increasing Investment on Research Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Recombinant Protein Drugs, by Application, Category and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Recombinant Protein Drugs (Value)
      • 5.2.1. Global Recombinant Protein Drugs by: Application (Value)
        • 5.2.1.1. Medicine
        • 5.2.1.2. Research
        • 5.2.1.3. Biotechnology
        • 5.2.1.4. Others
      • 5.2.2. Global Recombinant Protein Drugs by: Category (Value)
        • 5.2.2.1. Protein
        • 5.2.2.2. Monoclonal Antibody
        • 5.2.2.3. Vaccine
        • 5.2.2.4. Cytokines
        • 5.2.2.5. Others
      • 5.2.3. Global Recombinant Protein Drugs Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Recombinant Protein Drugs (Volume)
      • 5.3.1. Global Recombinant Protein Drugs by: Application (Volume)
        • 5.3.1.1. Medicine
        • 5.3.1.2. Research
        • 5.3.1.3. Biotechnology
        • 5.3.1.4. Others
      • 5.3.2. Global Recombinant Protein Drugs by: Category (Volume)
        • 5.3.2.1. Protein
        • 5.3.2.2. Monoclonal Antibody
        • 5.3.2.3. Vaccine
        • 5.3.2.4. Cytokines
        • 5.3.2.5. Others
      • 5.3.3. Global Recombinant Protein Drugs Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Recombinant Protein Drugs (Price)
  • 6. Recombinant Protein Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abcam PLC (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abnova Corporation (Taiwan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Enzo Life Sciences Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eurogentec (Belgium)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. ProSpec-Tany TechnoGene Ltd. (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Thermo Fisher Scientific Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck Serono (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Kyowa Hakko Kirin (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. BD Biosciences (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Albumedix Ltd. (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Recombinant Protein Drugs Sale, by Application, Category and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Recombinant Protein Drugs (Value)
      • 7.2.1. Global Recombinant Protein Drugs by: Application (Value)
        • 7.2.1.1. Medicine
        • 7.2.1.2. Research
        • 7.2.1.3. Biotechnology
        • 7.2.1.4. Others
      • 7.2.2. Global Recombinant Protein Drugs by: Category (Value)
        • 7.2.2.1. Protein
        • 7.2.2.2. Monoclonal Antibody
        • 7.2.2.3. Vaccine
        • 7.2.2.4. Cytokines
        • 7.2.2.5. Others
      • 7.2.3. Global Recombinant Protein Drugs Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Recombinant Protein Drugs (Volume)
      • 7.3.1. Global Recombinant Protein Drugs by: Application (Volume)
        • 7.3.1.1. Medicine
        • 7.3.1.2. Research
        • 7.3.1.3. Biotechnology
        • 7.3.1.4. Others
      • 7.3.2. Global Recombinant Protein Drugs by: Category (Volume)
        • 7.3.2.1. Protein
        • 7.3.2.2. Monoclonal Antibody
        • 7.3.2.3. Vaccine
        • 7.3.2.4. Cytokines
        • 7.3.2.5. Others
      • 7.3.3. Global Recombinant Protein Drugs Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Recombinant Protein Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Recombinant Protein Drugs: by Application(USD Million)
  • Table 2. Recombinant Protein Drugs Medicine , by Region USD Million (2015-2020)
  • Table 3. Recombinant Protein Drugs Research , by Region USD Million (2015-2020)
  • Table 4. Recombinant Protein Drugs Biotechnology , by Region USD Million (2015-2020)
  • Table 5. Recombinant Protein Drugs Others , by Region USD Million (2015-2020)
  • Table 6. Recombinant Protein Drugs: by Category(USD Million)
  • Table 7. Recombinant Protein Drugs Protein , by Region USD Million (2015-2020)
  • Table 8. Recombinant Protein Drugs Monoclonal Antibody , by Region USD Million (2015-2020)
  • Table 9. Recombinant Protein Drugs Vaccine , by Region USD Million (2015-2020)
  • Table 10. Recombinant Protein Drugs Cytokines , by Region USD Million (2015-2020)
  • Table 11. Recombinant Protein Drugs Others , by Region USD Million (2015-2020)
  • Table 12. South America Recombinant Protein Drugs, by Country USD Million (2015-2020)
  • Table 13. South America Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 14. South America Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 15. Brazil Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 16. Brazil Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 17. Argentina Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 18. Argentina Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 19. Rest of South America Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 20. Rest of South America Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 21. Asia Pacific Recombinant Protein Drugs, by Country USD Million (2015-2020)
  • Table 22. Asia Pacific Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 23. Asia Pacific Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 24. China Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 25. China Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 26. Japan Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 27. Japan Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 28. India Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 29. India Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 30. South Korea Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 31. South Korea Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 32. Taiwan Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 33. Taiwan Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 34. Australia Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 35. Australia Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 36. Rest of Asia-Pacific Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 37. Rest of Asia-Pacific Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 38. Europe Recombinant Protein Drugs, by Country USD Million (2015-2020)
  • Table 39. Europe Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 40. Europe Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 41. Germany Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 42. Germany Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 43. France Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 44. France Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 45. Italy Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 46. Italy Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 47. United Kingdom Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 48. United Kingdom Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 49. Netherlands Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 50. Netherlands Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 51. Rest of Europe Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 52. Rest of Europe Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 53. MEA Recombinant Protein Drugs, by Country USD Million (2015-2020)
  • Table 54. MEA Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 55. MEA Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 56. Middle East Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 57. Middle East Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 58. Africa Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 59. Africa Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 60. North America Recombinant Protein Drugs, by Country USD Million (2015-2020)
  • Table 61. North America Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 62. North America Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 63. United States Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 64. United States Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 65. Canada Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 66. Canada Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 67. Mexico Recombinant Protein Drugs, by Application USD Million (2015-2020)
  • Table 68. Mexico Recombinant Protein Drugs, by Category USD Million (2015-2020)
  • Table 69. Recombinant Protein Drugs Sales: by Application(ml)
  • Table 70. Recombinant Protein Drugs Sales Medicine , by Region ml (2015-2020)
  • Table 71. Recombinant Protein Drugs Sales Research , by Region ml (2015-2020)
  • Table 72. Recombinant Protein Drugs Sales Biotechnology , by Region ml (2015-2020)
  • Table 73. Recombinant Protein Drugs Sales Others , by Region ml (2015-2020)
  • Table 74. Recombinant Protein Drugs Sales: by Category(ml)
  • Table 75. Recombinant Protein Drugs Sales Protein , by Region ml (2015-2020)
  • Table 76. Recombinant Protein Drugs Sales Monoclonal Antibody , by Region ml (2015-2020)
  • Table 77. Recombinant Protein Drugs Sales Vaccine , by Region ml (2015-2020)
  • Table 78. Recombinant Protein Drugs Sales Cytokines , by Region ml (2015-2020)
  • Table 79. Recombinant Protein Drugs Sales Others , by Region ml (2015-2020)
  • Table 80. South America Recombinant Protein Drugs Sales, by Country ml (2015-2020)
  • Table 81. South America Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 82. South America Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 83. Brazil Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 84. Brazil Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 85. Argentina Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 86. Argentina Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 87. Rest of South America Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 88. Rest of South America Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 89. Asia Pacific Recombinant Protein Drugs Sales, by Country ml (2015-2020)
  • Table 90. Asia Pacific Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 91. Asia Pacific Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 92. China Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 93. China Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 94. Japan Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 95. Japan Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 96. India Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 97. India Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 98. South Korea Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 99. South Korea Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 100. Taiwan Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 101. Taiwan Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 102. Australia Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 103. Australia Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 104. Rest of Asia-Pacific Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 105. Rest of Asia-Pacific Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 106. Europe Recombinant Protein Drugs Sales, by Country ml (2015-2020)
  • Table 107. Europe Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 108. Europe Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 109. Germany Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 110. Germany Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 111. France Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 112. France Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 113. Italy Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 114. Italy Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 115. United Kingdom Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 116. United Kingdom Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 117. Netherlands Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 118. Netherlands Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 119. Rest of Europe Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 120. Rest of Europe Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 121. MEA Recombinant Protein Drugs Sales, by Country ml (2015-2020)
  • Table 122. MEA Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 123. MEA Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 124. Middle East Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 125. Middle East Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 126. Africa Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 127. Africa Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 128. North America Recombinant Protein Drugs Sales, by Country ml (2015-2020)
  • Table 129. North America Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 130. North America Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 131. United States Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 132. United States Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 133. Canada Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 134. Canada Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 135. Mexico Recombinant Protein Drugs Sales, by Application ml (2015-2020)
  • Table 136. Mexico Recombinant Protein Drugs Sales, by Category ml (2015-2020)
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Company Basic Information, Sales Area and Its Competitors
  • Table 147. Recombinant Protein Drugs: by Application(USD Million)
  • Table 148. Recombinant Protein Drugs Medicine , by Region USD Million (2021-2026)
  • Table 149. Recombinant Protein Drugs Research , by Region USD Million (2021-2026)
  • Table 150. Recombinant Protein Drugs Biotechnology , by Region USD Million (2021-2026)
  • Table 151. Recombinant Protein Drugs Others , by Region USD Million (2021-2026)
  • Table 152. Recombinant Protein Drugs: by Category(USD Million)
  • Table 153. Recombinant Protein Drugs Protein , by Region USD Million (2021-2026)
  • Table 154. Recombinant Protein Drugs Monoclonal Antibody , by Region USD Million (2021-2026)
  • Table 155. Recombinant Protein Drugs Vaccine , by Region USD Million (2021-2026)
  • Table 156. Recombinant Protein Drugs Cytokines , by Region USD Million (2021-2026)
  • Table 157. Recombinant Protein Drugs Others , by Region USD Million (2021-2026)
  • Table 158. South America Recombinant Protein Drugs, by Country USD Million (2021-2026)
  • Table 159. South America Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 160. South America Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 161. Brazil Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 162. Brazil Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 163. Argentina Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 164. Argentina Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 165. Rest of South America Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 166. Rest of South America Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 167. Asia Pacific Recombinant Protein Drugs, by Country USD Million (2021-2026)
  • Table 168. Asia Pacific Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 169. Asia Pacific Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 170. China Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 171. China Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 172. Japan Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 173. Japan Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 174. India Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 175. India Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 176. South Korea Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 177. South Korea Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 178. Taiwan Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 179. Taiwan Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 180. Australia Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 181. Australia Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 182. Rest of Asia-Pacific Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 183. Rest of Asia-Pacific Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 184. Europe Recombinant Protein Drugs, by Country USD Million (2021-2026)
  • Table 185. Europe Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 186. Europe Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 187. Germany Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 188. Germany Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 189. France Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 190. France Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 191. Italy Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 192. Italy Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 193. United Kingdom Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 194. United Kingdom Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 195. Netherlands Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 196. Netherlands Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 197. Rest of Europe Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 198. Rest of Europe Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 199. MEA Recombinant Protein Drugs, by Country USD Million (2021-2026)
  • Table 200. MEA Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 201. MEA Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 202. Middle East Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 203. Middle East Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 204. Africa Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 205. Africa Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 206. North America Recombinant Protein Drugs, by Country USD Million (2021-2026)
  • Table 207. North America Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 208. North America Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 209. United States Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 210. United States Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 211. Canada Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 212. Canada Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 213. Mexico Recombinant Protein Drugs, by Application USD Million (2021-2026)
  • Table 214. Mexico Recombinant Protein Drugs, by Category USD Million (2021-2026)
  • Table 215. Recombinant Protein Drugs Sales: by Application(ml)
  • Table 216. Recombinant Protein Drugs Sales Medicine , by Region ml (2021-2026)
  • Table 217. Recombinant Protein Drugs Sales Research , by Region ml (2021-2026)
  • Table 218. Recombinant Protein Drugs Sales Biotechnology , by Region ml (2021-2026)
  • Table 219. Recombinant Protein Drugs Sales Others , by Region ml (2021-2026)
  • Table 220. Recombinant Protein Drugs Sales: by Category(ml)
  • Table 221. Recombinant Protein Drugs Sales Protein , by Region ml (2021-2026)
  • Table 222. Recombinant Protein Drugs Sales Monoclonal Antibody , by Region ml (2021-2026)
  • Table 223. Recombinant Protein Drugs Sales Vaccine , by Region ml (2021-2026)
  • Table 224. Recombinant Protein Drugs Sales Cytokines , by Region ml (2021-2026)
  • Table 225. Recombinant Protein Drugs Sales Others , by Region ml (2021-2026)
  • Table 226. South America Recombinant Protein Drugs Sales, by Country ml (2021-2026)
  • Table 227. South America Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 228. South America Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 229. Brazil Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 230. Brazil Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 231. Argentina Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 232. Argentina Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 233. Rest of South America Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 234. Rest of South America Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 235. Asia Pacific Recombinant Protein Drugs Sales, by Country ml (2021-2026)
  • Table 236. Asia Pacific Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 237. Asia Pacific Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 238. China Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 239. China Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 240. Japan Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 241. Japan Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 242. India Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 243. India Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 244. South Korea Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 245. South Korea Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 246. Taiwan Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 247. Taiwan Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 248. Australia Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 249. Australia Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 250. Rest of Asia-Pacific Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 251. Rest of Asia-Pacific Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 252. Europe Recombinant Protein Drugs Sales, by Country ml (2021-2026)
  • Table 253. Europe Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 254. Europe Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 255. Germany Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 256. Germany Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 257. France Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 258. France Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 259. Italy Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 260. Italy Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 261. United Kingdom Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 262. United Kingdom Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 263. Netherlands Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 264. Netherlands Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 265. Rest of Europe Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 266. Rest of Europe Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 267. MEA Recombinant Protein Drugs Sales, by Country ml (2021-2026)
  • Table 268. MEA Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 269. MEA Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 270. Middle East Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 271. Middle East Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 272. Africa Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 273. Africa Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 274. North America Recombinant Protein Drugs Sales, by Country ml (2021-2026)
  • Table 275. North America Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 276. North America Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 277. United States Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 278. United States Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 279. Canada Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 280. Canada Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 281. Mexico Recombinant Protein Drugs Sales, by Application ml (2021-2026)
  • Table 282. Mexico Recombinant Protein Drugs Sales, by Category ml (2021-2026)
  • Table 283. Research Programs/Design for This Report
  • Table 284. Key Data Information from Secondary Sources
  • Table 285. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Recombinant Protein Drugs: by Application USD Million (2015-2020)
  • Figure 5. Global Recombinant Protein Drugs: by Category USD Million (2015-2020)
  • Figure 6. South America Recombinant Protein Drugs Share (%), by Country
  • Figure 7. Asia Pacific Recombinant Protein Drugs Share (%), by Country
  • Figure 8. Europe Recombinant Protein Drugs Share (%), by Country
  • Figure 9. MEA Recombinant Protein Drugs Share (%), by Country
  • Figure 10. North America Recombinant Protein Drugs Share (%), by Country
  • Figure 11. Global Recombinant Protein Drugs: by Application ml (2015-2020)
  • Figure 12. Global Recombinant Protein Drugs: by Category ml (2015-2020)
  • Figure 13. South America Recombinant Protein Drugs Share (%), by Country
  • Figure 14. Asia Pacific Recombinant Protein Drugs Share (%), by Country
  • Figure 15. Europe Recombinant Protein Drugs Share (%), by Country
  • Figure 16. MEA Recombinant Protein Drugs Share (%), by Country
  • Figure 17. North America Recombinant Protein Drugs Share (%), by Country
  • Figure 18. Global Recombinant Protein Drugs share by Players 2020 (%)
  • Figure 19. Global Recombinant Protein Drugs share by Players (Top 3) 2020(%)
  • Figure 20. Global Recombinant Protein Drugs share by Players (Top 5) 2020(%)
  • Figure 21. BCG Matrix for key Companies
  • Figure 22. Abcam PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. Abcam PLC (United Kingdom) Revenue: by Geography 2020
  • Figure 24. Abnova Corporation (Taiwan) Revenue, Net Income and Gross profit
  • Figure 25. Abnova Corporation (Taiwan) Revenue: by Geography 2020
  • Figure 26. Enzo Life Sciences Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Enzo Life Sciences Inc. (United States) Revenue: by Geography 2020
  • Figure 28. Eurogentec (Belgium) Revenue, Net Income and Gross profit
  • Figure 29. Eurogentec (Belgium) Revenue: by Geography 2020
  • Figure 30. ProSpec-Tany TechnoGene Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 31. ProSpec-Tany TechnoGene Ltd. (Israel) Revenue: by Geography 2020
  • Figure 32. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2020
  • Figure 34. Merck Serono (Germany) Revenue, Net Income and Gross profit
  • Figure 35. Merck Serono (Germany) Revenue: by Geography 2020
  • Figure 36. Kyowa Hakko Kirin (Japan) Revenue, Net Income and Gross profit
  • Figure 37. Kyowa Hakko Kirin (Japan) Revenue: by Geography 2020
  • Figure 38. BD Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 39. BD Biosciences (United States) Revenue: by Geography 2020
  • Figure 40. Albumedix Ltd. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 41. Albumedix Ltd. (United Kingdom) Revenue: by Geography 2020
  • Figure 42. Global Recombinant Protein Drugs: by Application USD Million (2021-2026)
  • Figure 43. Global Recombinant Protein Drugs: by Category USD Million (2021-2026)
  • Figure 44. South America Recombinant Protein Drugs Share (%), by Country
  • Figure 45. Asia Pacific Recombinant Protein Drugs Share (%), by Country
  • Figure 46. Europe Recombinant Protein Drugs Share (%), by Country
  • Figure 47. MEA Recombinant Protein Drugs Share (%), by Country
  • Figure 48. North America Recombinant Protein Drugs Share (%), by Country
  • Figure 49. Global Recombinant Protein Drugs: by Application ml (2021-2026)
  • Figure 50. Global Recombinant Protein Drugs: by Category ml (2021-2026)
  • Figure 51. South America Recombinant Protein Drugs Share (%), by Country
  • Figure 52. Asia Pacific Recombinant Protein Drugs Share (%), by Country
  • Figure 53. Europe Recombinant Protein Drugs Share (%), by Country
  • Figure 54. MEA Recombinant Protein Drugs Share (%), by Country
  • Figure 55. North America Recombinant Protein Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abcam PLC (United Kingdom)
  • Abnova Corporation (Taiwan)
  • Enzo Life Sciences Inc. (United States)
  • Eurogentec (Belgium)
  • ProSpec-Tany TechnoGene Ltd. (Israel)
  • Thermo Fisher Scientific Inc. (United States)
  • Merck Serono (Germany)
  • Kyowa Hakko Kirin (Japan)
  • BD Biosciences (United States)
  • Albumedix Ltd. (United Kingdom)
Additional players considered in the study are as follows:
ACROBiosystems Inc. (United States) , Sino Biological Inc. (China) , Scil Proteins GmbH (Germany)
Select User Access Type

Key Highlights of Report


Nov 2021 244 Pages 96 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Recombinant Protein Drugs research Quantitative research analysis
Global Recombinant Protein Drugs research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Recombinant Protein Drugs Market is heading robustly to achieve new growth cycle.
The Concentration Rate of Global Recombinant Protein Drugs market is dominated by United States Players to generate healthy valuation by 2026.
Companies that are profiled in Global Recombinant Protein Drugs Market are Abcam PLC (United Kingdom), Abnova Corporation (Taiwan), Enzo Life Sciences Inc. (United States), Eurogentec (Belgium), ProSpec-Tany TechnoGene Ltd. (Israel), Thermo Fisher Scientific Inc. (United States), Merck Serono (Germany), Kyowa Hakko Kirin (Japan), BD Biosciences (United States) and Albumedix Ltd. (United Kingdom) etc.

Know More About Global Recombinant Protein Drugs research Report?

Have a Query? Click Here

Other Related Reports

Metallic Nanoparticles Comprehensive Study by Synthesis Method (Chemical Methods, Physical Methods, Bio-Based Methods), End-Use Industry (Pharmaceutical & Healthcare, Electrical & Electronics, Cataly...
$ 3650
Injectable Drug Delivery Formulation Comprehensive Study by Type (Conventional Drug Delivery Formulations, Novel Drug Delivery Formulations, Long-acting Formulations), Application (Autoimmune Disease...
$ 3450
Competent Cells Comprehensive Study by Type (Cloned Competent Cells, Agrobacterium Tumefaciens Competent Cells, Expression Competent Cells), Application (Cloning {Subcloning & Routine Cloning, Phage ...
$ 3750
Oral Vaccines Comprehensive Study by Type (Live (attenuated), Inactive, Recombinant, Other), Application (Polio, Rabies, Tuberculosis, Influenza, Respiratory infections, HIV, Cholera, Rotavirus, Othe...
$ 3450
Biobanking Comprehensive Study by Type (Equipment, Consumables, Services, Software), Application (Regenerative Medicine, Life Science Research, Clinical Research), Ownership (National/Regional Agenci...
$ 3750
Clinical Microbiology Comprehensive Study by Application (Pharmaceutical, Food Testing, Energy, Chemical and Material Manufacturing, Environment), End Users (Hospital, Diagnolab, Academia), Disease (...
$ 3750